IMDX
Insight Molecular Diagnostics
IMDX
IMDX
60 hedge funds and large institutions have $78.4M invested in Insight Molecular Diagnostics in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 28 increasing their positions, 9 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
0.11% more ownership
Funds ownership: 2.33% → 2.44% (+0.11%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
60
Holding in Top 10
1
Calls
$447K
Puts
$143K
Top Buyers
| 1 | +$1.88M | |
| 2 | +$622K | |
| 3 | +$592K | |
| 4 |
BlackRock
New York
|
+$499K |
| 5 |
PM
Penbrook Management
New York
|
+$465K |
Top Sellers
| 1 | -$426K | |
| 2 | -$375K | |
| 3 | -$278K | |
| 4 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$226K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$95.6K |